Among these, KRAS mutations are more common in adenocarcinomas, and high levels of activating mutations are associated with poor prognosis.[22–25] In the development of HPV-related cervical cancer, somatic mutations occur in the cells, activating oncogenes and inactivating tumor suppressor genes. This evidence concerns the gene KRAS and adenocarcinoma.